David B. Finlay

发表

GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine

M. Glass, N. Grimsey, Michelle Glass, 2016, PeerJ.

Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.

M. Glass, J. Javitch, N. Grimsey, 2020, Biochemical pharmacology.

Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence

M. Glass, J. Javitch, N. Grimsey, 2019, Front. Pharmacol..

Gαs signalling of the CB1 receptor and the influence of receptor number

M. Glass, N. Grimsey, Anisha Korde, 2017, British journal of pharmacology.

Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA.

M. Glass, J. Javitch, David B. Finlay, 2019, ACS chemical neuroscience.

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior.

M. Glass, T. Gamage, David B. Finlay, 2021, Journal of medicinal chemistry.

A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models

M. Glass, M. Schapira, H. Thorpe, 2020, Neuropsychopharmacology.

Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases

M. Glass, J. Javitch, N. Grimsey, 2021, British journal of pharmacology.

An evaluation of the operational model when applied to quantify functional selectivity

M. Glass, S. Duffull, David B. Finlay, 2018, British journal of pharmacology.

Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite

M. Glass, R. Rosengren, Shuli Chen, 2022, Forensic Toxicology.

Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018

M. Glass, B. Thomas, J. Wiley, 2022, Pharmacology research & perspectives.

Real-Time Measurement of Cannabinoid Receptor-Mediated cAMP Signaling.

M. Glass, N. Grimsey, David B. Finlay, 2017, Methods in enzymology.

Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling

M. Glass, S. Duffull, David B. Finlay, 2020, British journal of pharmacology.

Development of positive control tissue for in situ hybridisation using Alvetex scaffolds

E. S. Graham, M. Glass, David B. Finlay, 2014, Journal of Neuroscience Methods.

Exploring group size for statistical analysis of real‐time signalling experiments

M. Glass, S. Duffull, David B. Finlay, 2021, British journal of pharmacology.

Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors

M. Glass, David B. Finlay, Callum M. S. Jones, 2020, Frontiers in Pharmacology.

100 years of modelling ligand–receptor binding and response: A focus on GPCRs

Stephen B Duffull, David B Finlay, Michelle Glass, 2020, British journal of pharmacology.

Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias

M. Glass, David B. Finlay, Jamie J Manning, 2021, Neuropharmacology.

Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues.

M. Glass, D. Hibbs, I. McGregor, 2022, ACS chemical neuroscience.

Model‐free and kinetic modelling approaches for characterising non‐equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors

M. Glass, S. Duffull, David B. Finlay, 2019, British journal of pharmacology.

Chapter 59 – Signaling and Regulation of the Cannabinoid CB1 Receptor

M. Glass, David B. Finlay, Morag R Hunter, 2017 .

Factors influencing the specificity and bias of CB1 cannabinoid receptor signalling

David B. Finlay, 2018 .

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

H. de Vries, L. Heitman, M. Glass, 2017, Nature Communications.

In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?

M. Glass, S. Duffull, R. Ross, 2022, ACS pharmacology & translational science.

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

M. Glass, Thuy-Ai T Nguyen, T. Gamage, 2021, Bioorganic & medicinal chemistry.

Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.

M. Glass, David B. Finlay, Monica Patel, 2020, Cellular signalling.

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism

M. Glass, J. Wiley, R. Rosengren, 2023, Pharmacology Biochemistry and Behavior.

In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018

M. Glass, I. McGregor, B. Thomas, 2020, Pharmacology Biochemistry and Behavior.

Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence

M. Glass, David B. Finlay, Gabriel Rawcliffe, 2022, British journal of pharmacology.

Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

U. Spampinato, Y. Shaham, M. Glass, 2023, Nature Medicine.

Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics.

David B. Finlay, Jamie J. Manning, Hayley M Green, 2024, British journal of pharmacology.

GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the type-1 cannabinoid receptor and the consequences on G protein signalling

David B. Finlay, Jamie J. Manning, Michelle Glass, 2024, Biochemical Pharmacology.

Determination of the Cannabinoid CB1 Receptor’s Positive Allosteric Modulator Binding Site through Mutagenesis Studies

David B. Finlay, D. Furkert, Daniel M. J. Fellner, 2024, Pharmaceuticals.

RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB1, CB2, GPR18 and GPR55 cannabinoid receptors

N. Grimsey, K. Mountjoy, David B. Finlay, 2023, British journal of pharmacology.

Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor.

David B. Finlay, S. Banister, Eric Sparkes, 2024, Biochemical pharmacology.